Srikumar M Raja
Overview
Explore the profile of Srikumar M Raja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Naramura M, Nadeau S, Mohapatra B, Ahmad G, Mukhopadhyay C, Sattler M, et al.
Oncotarget
. 2011 Mar;
2(3):245-50.
PMID: 21422499
Casitas B-lineage lymphoma (Cbl) family proteins are evolutionarily-conserved attenuators of protein tyrosine kinase (PTK) signaling. Biochemical analyses over the past two decades have firmly established that the negative regulatory functions...
12.
Raja S, Clubb R, Ortega-Cava C, Williams S, Bailey T, Duan L, et al.
Cancer Biol Ther
. 2010 Nov;
11(2):263-76.
PMID: 21088503
The receptor tyrosine kinase ErbB2 is overexpressed in up to a third of breast cancers, allowing targeted therapy with ErbB2-directed humanized antibodies such as Trastuzumab. Concurrent targeting of ErbB2 stability...
13.
Duan L, Raja S, Chen G, Virmani S, Williams S, Clubb R, et al.
J Biol Chem
. 2010 Oct;
286(1):620-33.
PMID: 20940296
The E3 ubiquitin ligase Casitas B lymphoma protein (Cbl) controls the ubiquitin-dependent degradation of EGF receptor (EGFR), but its role in regulating downstream signaling elements with which it associates and...
14.
Standley S, Toft D, Cheng H, Soukasene S, Chen J, Raja S, et al.
Cancer Res
. 2010 Apr;
70(8):3020-6.
PMID: 20354185
Nanotechnology offers novel delivery vehicles for cancer therapeutics. Potential advantages of nanoscale platforms include improved pharmacokinetics, encapsulation of cytotoxic agents, enhanced accumulation of therapeutics in the tumor microenvironment, and improved...
15.
Chung B, Raja S, Clubb R, Tu C, George M, Band V, et al.
BMC Cell Biol
. 2009 Dec;
10:84.
PMID: 19948031
Background: Epidermal growth factor receptor (EGFR) controls a wide range of cellular processes, and altered EGFR signaling contributes to human cancer. EGFR kinase domain mutants found in non-small cell lung...
16.
Duan L, Chen G, Virmani S, Ying G, Raja S, Chung B, et al.
J Biol Chem
. 2009 Oct;
285(2):1555-68.
PMID: 19826000
Non-malignant mammary epithelial cells (MECs) undergo acinar morphogenesis in three-dimensional Matrigel culture, a trait that is lost upon oncogenic transformation. Rho GTPases are thought to play important roles in regulating...
17.
Metkar S, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M, et al.
Immunity
. 2008 Oct;
29(5):720-33.
PMID: 18951048
Granzyme A (GzmA) is considered a major proapoptotic protease. We have discovered that GzmA-induced cell death involves rapid membrane damage that depends on the synergy between micromolar concentrations of GzmA...
18.
Raja S, Clubb R, Bhattacharyya M, Dimri M, Cheng H, Pan W, et al.
Cancer Biol Ther
. 2008 Sep;
7(10):1630-40.
PMID: 18769124
ErbB2 (or Her2/Neu) overexpression in breast cancer signifies poorer prognosis, yet it has provided an avenue for targeted therapy as demonstrated by the success of the humanized monoclonal antibody Trastuzumab...
19.
Izaguirre G, Swanson R, Raja S, Rezaie A, Olson S
J Biol Chem
. 2007 Sep;
282(46):33609-33622.
PMID: 17875649
Heparin activates the serpin, antithrombin, to inhibit its target blood-clotting proteases by generating new protease interaction exosites. To resolve the effects of these exosites on the initial Michaelis docking step...
20.
Raja S, Metkar S, Honing S, Wang B, Russin W, Pipalia N, et al.
J Biol Chem
. 2005 Mar;
280(21):20752-61.
PMID: 15788411
The molecular interaction of secreted granzyme B-serglycin complexes with target cells remains undefined. Targets exposed to double-labeled granzyme B-serglycin complexes show solely the uptake of granzyme B. An in vitro...